TrialJournal for immunotherapy of cancer2021

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.

Danny Rischin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.